Humoral and Cellular Immune Responses After a 3-dose Course of mRNA-1273 COVID-19 Vaccine in Kidney Transplant Recipients: A Prospective Cohort Study.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
01
08
2022
accepted:
10
08
2022
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
In kidney transplant recipients, there is discordance between the development of cellular and humoral response after vaccination against SARS-CoV-2. We sought to determine the interplay between the 2 arms of adaptive immunity in a 3-dose course of mRNA-1273 100 μg vaccine. Humoral (IgG/IgM) and cellular (N- and S-ELISpot) responses were studied in 117 kidney and 12 kidney-pancreas transplant recipients at the following time points: before the first dose, 14 d after the second dose' and before and after the third dose, with a median of 203 and 232 d after the start of the vaccination cycle, respectively. After the second dose, 26.7% of naive cases experienced seroconversion. Before the third dose and in the absence of COVID-19, this percentage increased to 61.9%. After the third dose, seroconversion occurred in 80.0% of patients. Naive patients who had at any time point a detectable positivity for S-ELISpot were 75.2% of the population, whereas patients who maintained S-ELISpot positivity throughout the study were 34.3%. S-ELISpot positivity at 42 d was associated with final seroconversion (odds ratio' 3.14; 95% confidence interval' 1.10-8.96; A substantial proportion of kidney transplant recipients developed late seroconversion after 2 doses. Cellular immunity was associated with the development of a stronger humoral response.
Identifiants
pubmed: 36245998
doi: 10.1097/TXD.0000000000001389
pmc: PMC9553402
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1389Informations de copyright
Copyright © 2022 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
Transplantation. 2021 Dec 1;105(12):e278-e279
pubmed: 34406187
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
J Med Virol. 2022 Jan;94(1):388-392
pubmed: 34415572
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
EBioMedicine. 2021 Nov;73:103679
pubmed: 34763205
J Am Soc Nephrol. 2021 Oct 19;:
pubmed: 34667083
Am J Transplant. 2021 Aug;21(8):2727-2739
pubmed: 34036720
Immunity. 2021 Jan 12;54(1):14-18
pubmed: 33406391
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
JAMA. 2021 Jul 23;:
pubmed: 34297036
Transplantation. 2022 Apr 1;106(4):821-834
pubmed: 34753894
J Infect Dis. 2021 Dec 1;224(11):1849-1860
pubmed: 34739078
Am J Transplant. 2021 Dec;21(12):3980-3989
pubmed: 34347934
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33956667
J Am Soc Nephrol. 2021 Oct 1;:
pubmed: 34599041
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Transplant Direct. 2021 Nov 17;7(12):e794
pubmed: 34805496
JAMA Intern Med. 2022 Feb 1;182(2):165-171
pubmed: 34928302
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Front Immunol. 2021 May 28;12:635942
pubmed: 34127926
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
Am J Transplant. 2020 Nov;20(11):3030-3041
pubmed: 32777153